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Abstract
In the recent years, increased understanding of the molecular profiles of non-small cell lung cancer (NSCLC) has
allowed for targeted treatment of actionable genetic mutations. The management of NSCLC now requires multiple
molecular tests to guide the treatment strategy. In the light of this, there is a need to establish a molecular testing
consensus statement for advanced NSCLC patients in Malaysia. This Malaysian consensus statement was developed
by a panel of experts, chaired by a pathologist and composed of three other pathologists, four respiratory physicians
and three oncologists. It reflects currently available scientific data and adaptations of recommendations from
international guidelines to the local landscape. Expert recommendations on different aspects of molecular testing
agreed upon by the panel are provided as structured discussions. These recommendations address the appropriate
patients and samples to be tested, as well as when and how these tests should be performed. The algorithms for
molecular testing in metastatic NSCLC, in the first line setting and upon disease progression beyond first line therapy,
were developed. © 2019 The Authors
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